For more than a decade, Mount Sinai physician-scientists have actively participated in multicenter clinical trials researching medications that potentially can be helpful for patients with ILD. While no treatment has emerged capable of reversing the disease, some hold promise of impacting the progression of the illness.

Maria Padilla, MD, Clinical Director of the Advanced Lung/ILD Program,has a number of clinical trials underway on potential treatments for idiopathic pulmonary fibrosis, the most common form of interstitial lung disease, which is often caused by environmental toxins.

Recently completed trials of medications used to treat idiopathic pulmonary fibrosis (IPF), have successfully met their targeted outcome endpoints, and the Federal Drug Administration (FDA) will be reviewing the medications for use in treating IPF. Mount Sinai’s lung diseases research team for IPF, has engaged in many trials studying the efficacy of various agents including those being considered for submission to the FDA.

Because of our unique experience in pulmonary asbestosis, sarcoidosis, and collagen-vascular diseases, the Mount Sinai Health System Division of Pulmonary and Critical Care has become a center for the study of interstitial lung diseases concentrating on:

  • Pathophysiology
  • Epidemiology
  • Diagnosis
  • Treatment
  • Support
  • Scientific investigation

We offer comprehensive sophisticated techniques including bronchoscopic biopsy and lavage, open lung biopsy, computerized diagnostic chest tomography (CT scans), and nuclear medicine scans. Our physicians have extensive experience in the care of patients with diffuse lung disease including novel medication, and oxygen therapy.